Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective
| Autor: | Gareth J. Veal, Mark C. Barnfield, Eve Roberts, Jasper Mogg |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Renal function Antineoplastic Agents urologic and male genital diseases Body weight Carboplatin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Assessment data Neoplasms medicine Pediatric oncology Humans Dosing Child medicine.diagnostic_test business.industry Infant Newborn Cancer Infant Hematology medicine.disease United Kingdom Oncology chemistry Therapeutic drug monitoring 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Female business 030215 immunology Glomerular Filtration Rate |
| Zdroj: | Pediatric hematology and oncology. 37(3) |
| ISSN: | 1521-0669 |
| Popis: | Renal function-based carboplatin dosing is a well-accepted practice in pediatric oncology. However, the accuracy of this approach is only as precise as the method of kidney function measurement, most commonly involving determination of glomerular filtration rate (GFR). Recent work by the Children's Oncology Group has raised concerns over nuclear medicine-based methodologies used to calculate GFR across US clinical centers. Current practices of GFR measurement, methods used to calculate carboplatin dosage and the utility of therapeutic drug monitoring were investigated in 21 UK primary pediatric oncology treatment centers through a questionnaire-based study. Information obtained was compared to results previously published in 2008 following a similar survey. In relation to GFR measurement, the main changes observed were a shift toward a greater number of samples being taken following tracer administration and an increase in number of centers using the Brochner-Mortensen correction factor. In relation to the use of renal function assessment data to inform dosing, EDTA elimination half-life in conjunction with body weight was used to calculate carboplatin dose in 18/21 (86%) centers, with uncorrected GFR and body weight utilized in 9/21 (43%) centers. A total of 14/21 (67%) centers utilize therapeutic drug monitoring approaches to carboplatin treatment in defined patient groups including neonates and infants. Results suggest that while GFR measurement across UK centers is relatively consistent, some uncertainties remain. In addition, for patient sub-populations where there are concerns over the potential for marked inter-patient variability in carboplatin exposures, adaptive dosing approaches are now well established. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|